Claims
- 1. A method for the treatment of ocular collagen connective tissue comprising:
identifying a portion of the ocular collagen connective tissue having a connector portion which transitions into the ciliary muscle of an eye; directing a source of energy at at least one selected site along the portion of the connective tissue, the amount of energy being sufficient to cause longitudinal shrinkage in the length of connective tissue.
- 2. A method as claimed in claim 1 wherein the energy source comprises a coherent light energy source for increasing the temperature of the connective tissue to produce a thermal phase transition thereof thereby causing the longitudinal shrinkage.
- 3. A method as claimed in claim 2 wherein coherent light energy source is an infrared laser.
- 4. A method as claimed in claim 2 wherein the increase in temperature of the connective tissue is controlled so that it falls within the range of the thermal shrinkage temperature of collagen (Ts).
- 5. A method as claimed in claim 4 wherein the thermal shrinkage temperature of collagen (Ts) is within about 5 degrees Celsius of about 23 degrees Celsius above ambient body temperature but below the temperature of coagulation and tissue destruction of the connective tissue.
- 6. A method as claimed in claim 1 wherein the amount of energy causing thermal shrinkage of the connective tissue is controlled so as to be atraumatic.
- 7. A method as claimed in claim 1 wherein the connective tissue site selected is one occupied by both tendinous insertion of the ciliary muscle and the trabecular meshwork of the aqueous filtration mechanism.
- 8. A method as claimed in claim 1 wherein the connective tissue selected for directing the source of energy is chosen so that the shrinkage opens the trabecular meshwork to increase the pore size and reduce resistance to aqueous outflow.
- 9. A method as claimed in claim 3 wherein the infrared laser emits light having a wavelength of about 1.32 microns with an extinction depth of about 800 to 1,000 microns.
- 10. A method as claimed in claim 3 wherein the infrared laser comprises a Neodymium:YAG laser operated at a repetition rate of from about 1 Hz to about 100 Hz.
- 11. A method as claimed in claim 1 wherein the source of energy is directed along a trans-scleral route to the connective tissue at the collagenous tendinous insertion of the ciliary muscle.
- 12. A method as claimed in claim 11 wherein the source of energy is directed to target the scleral spur.
- 13. A method as claimed in claim 1 wherein the energy is delivered by quartz fiber-optic probe having a diameter range of 200 to 320 micron, the probe being housed in a protective casing to provide a total outer diameter approximately equivalent to a 22 gauge needle.
- 14. A method as claimed in claim 13 further comprising the step of aiming a visible light beam along the probe to facilitate identification of the operative site.
- 15. A method as claimed in claim 1 further comprising the step of diagnostic gonioscopy to determine the filtration angle structure.
- 16. A method as claimed in claim 1 wherein the source of energy is applied in all four quadrants of the globe to shrink the connective tissue equally.
- 17. A method as claimed in claim 1 further comprising the step of staining the corneal and bulbar conjunctiva with fluorescein dye to facilitate delineation of the corneal-scleral trabecular meshwork.
- 18. A method as claimed in claim 10 wherein the Neodymium:YAG laser operates at about 300 microseconds pulse duration with a repetition rate of about 3 to 20 Hz and a power setting of about 1 to 6 watts.
- 19. A method as claimed in claim 18 wherein the laser has an energy per pulse of 6 Joules.
- 20. A method as claimed in claim 3 wherein the infrared laser comprises a 1.34 micron Neodymium:YAP laser operated so as to have an extinction depth near the depth of the target tissue.
- 21. A method as claimed in claim 14 wherein the aiming beam is a 0.5 mW Helium Neon 632.8 nm laser.
- 22. A method as claimed in claim 1 wherein the source of energy is selected from one or more of the following: microwave, radio frequency, ultrasound, sonic, electromagnetic, chemical or a combination of one or more thereof.
- 23. A method as claimed in claim 1 further comprising the step of applying a topical ophthalmic anesthetic.
- 24. A method as claimed in claim 1 further comprising the step of conducting heat away from the surface of the connective tissue.
- 25. A method as claimed in claim 24 wherein heat is removed from the surface by cryogen spray cooling.
- 26. A method as claimed in claim 24 wherein heat is conducted away from the surface of the connective tissue using passive cooling, dynamic cooling, or a combination thereof.
- 27. A method as claimed in claim 24 wherein heat is removed from the surface using a contact heat sink.
- 28. A method as claimed in claim 1 wherein the shrinkage in the connective tissue causes an increase in the functional mechanical advantage of the ciliary muscle to thereby increase the accommodative state of the lens of the eye.
- 29. A method as claimed in claim 1 wherein the shrinkage in the connective tissue causes a reduction of the resistance to aqueous outflow.
- 30. A system for the treatment of ocular collagen connective tissue comprising a probe, an energy source associated with the probe, the energy source being capable of providing thermal energy to cause an increase in temperature of the connective tissue to the thermal shrinkage temperature of collagen.
- 31. A system as claimed in claim 30 wherein the probe comprises a quartz fiber-optic probe having a diameter range of 200 to 320 micron, the probe being housed in a protective casing to provide a total outer diameter approximately equivalent to a 22 gauge needle.
- 32. A system as claimed in claim 30 further comprising a visible light beam located along the probe to facilitate identification of the operative site.
- 33. A system as claimed in claim 30 wherein the infrared laser comprises a Neodymium:YAG laser operating at about 300 microseconds pulse duration with a repetition rate of about 3 to 20 Hz and a power setting of about 1 to 6 watts.
- 34. A system as claimed in claim 30 wherein the laser has an energy per pulse of 6 Joules.
- 35. A system as claimed in claim 30 wherein the infrared laser comprises a 1.34 micron Neodymium:YAP laser operated so as to have an extinction depth near the depth of the target tissue.
- 36. A system as claimed in claim 32 wherein the Helium Neon laser beam is a 0.5 mW Helium Neon 632.8 nm laser.
- 37. A system as claimed in claim 30 wherein the energy source is one selected from following: infrared laser, microwave, radio frequency, ultrasound, sonic, electromagnetic, chemical or a combination of one or more thereof.
- 38. A system as claimed in claim 30 wherein heat is removed from the surface by cryogen spray cooling.
- 39. A system as claimed in claim 30 wherein heat is conducted away from the surface of the connective tissue using passive cooling, dynamic cooling, or a combination thereof.
- 40. A system as claimed in claim 38 wherein heat is removed from the surface using a contact heat sink.
- 41. A method for the treatment of presbyopia, the method comprising:
identifying a portion of ocular collagen connective tissue having a connector portion which transitions into the ciliary muscle of an eye; directing a source of energy at at least one selected site along the portion of the connective tissue, the amount of energy being sufficient to cause longitudinal shrinkage in the length of connective tissue.
- 42. A method for increasing the mechanical advantage of a muscle, the method comprising:
identifying a portion of collagen connective tissue extending between the muscle and the base to which the connective tissue is attached; directing a source of energy at at least one selected site along the portion of the connective tissue, the amount of energy being sufficient to cause longitudinal shrinkage in the length of connective tissue.
- 43. A method as claimed in claim 1 wherein the source of energy is directed to the portion of the ocular collagen connective tissue by means of a trans-scleral route directly to the said portion.
- 44. A method as claimed in claim 1 wherein the source of energy is directed to the portion of the ocular collagen connective tissue by directing the energy across the cornea and anterior chamber of the eye to a scleral spur ab interna.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/113,361 filed Mar. 29, 2002, which application claims the benefit of U.S. Provisional Applications Nos. 60/280,670 filed Mar. 30, 2001 and 60/311,518 filed Aug. 11, 2001, all of which are incorporated herein by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60280670 |
Mar 2001 |
US |
|
60311518 |
Aug 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10113361 |
Mar 2002 |
US |
Child |
10229762 |
Aug 2002 |
US |